Rachel Klemovitch, Assistant Editor05.08.24
Tetrous Inc., a leading regenerative medicine company, announced the completion of the first surgical cases using its EnFix TAC, the latest product that expands its line of EnFix implants for all surgical techniques for rotator cuff repair.
Nikhil Verma, MD, Professor and Director, Sports Medicine and Shoulder, Midwest Orthopedics at Rush, Head Team Physician, Chicago White Sox, who performed the first surgeries with the EnFix TAC told the press, "When it comes to surgical outcomes in rotator cuff repair, enthesis healing is one of the most critical factors. The EnFix implants address this crucial need with minimal disruption to the surgical procedure". He continued, "I believe these products will have a transformative impact on surgical protocols in rotator cuff repair."
The EnFix TAC is the second offering in the EnFix family of implants. It is available in two configurations, the TAC-O and TAC-T, to accommodate the varied availability of bone based on the size of the rotator cuff tear. The EnFix TAC options are designed to deliver the same enthesis healing properties in a graft that is intended for use independent of a suture anchor or with all-suture anchors.
EnFix technology utilizes proprietary demineralized cortical bone fibers to yield an osteoinductive and osteoconductive implant that promotes optimal biologic healing at the bone-to-tendon interface. Strong pre-clinical data and promising early clinical show healing at the bone-to-tendon interface. There is also growing evidence supporting the applicability of the EnFix technology to address the unmet need for technology that can improve the weak repair at the enthesis that is driving the high surgical failure rates in rotator cuff repairs.
EnFix was commercially released in June of 2023 and since then, over 400 grafts have been implanted in over 200 surgeries in the US and Australia.
Nikhil Verma, MD, Professor and Director, Sports Medicine and Shoulder, Midwest Orthopedics at Rush, Head Team Physician, Chicago White Sox, who performed the first surgeries with the EnFix TAC told the press, "When it comes to surgical outcomes in rotator cuff repair, enthesis healing is one of the most critical factors. The EnFix implants address this crucial need with minimal disruption to the surgical procedure". He continued, "I believe these products will have a transformative impact on surgical protocols in rotator cuff repair."
The EnFix TAC is the second offering in the EnFix family of implants. It is available in two configurations, the TAC-O and TAC-T, to accommodate the varied availability of bone based on the size of the rotator cuff tear. The EnFix TAC options are designed to deliver the same enthesis healing properties in a graft that is intended for use independent of a suture anchor or with all-suture anchors.
EnFix technology utilizes proprietary demineralized cortical bone fibers to yield an osteoinductive and osteoconductive implant that promotes optimal biologic healing at the bone-to-tendon interface. Strong pre-clinical data and promising early clinical show healing at the bone-to-tendon interface. There is also growing evidence supporting the applicability of the EnFix technology to address the unmet need for technology that can improve the weak repair at the enthesis that is driving the high surgical failure rates in rotator cuff repairs.
EnFix was commercially released in June of 2023 and since then, over 400 grafts have been implanted in over 200 surgeries in the US and Australia.